Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $63.00 price target on the biotechnology company's stock. HC Wainwright's price objective suggests a potential upside of 263.95% from the stock's previous close.
Separately, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a report on Monday, December 16th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $66.75.
Read Our Latest Report on Arcturus Therapeutics
Arcturus Therapeutics Price Performance
NASDAQ ARCT traded down $0.67 during trading on Monday, reaching $17.31. 391,866 shares of the company's stock were exchanged, compared to its average volume of 474,952. The business has a 50 day moving average price of $17.62 and a 200-day moving average price of $20.05. The stock has a market capitalization of $468.88 million, a P/E ratio of -7.80 and a beta of 2.63. Arcturus Therapeutics has a fifty-two week low of $14.30 and a fifty-two week high of $45.00.
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.70) by $0.44. The firm had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. During the same quarter in the prior year, the business posted ($0.61) EPS. On average, analysts forecast that Arcturus Therapeutics will post -2.31 earnings per share for the current year.
Insider Buying and Selling
In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the company's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $20.76, for a total transaction of $249,120.00. Following the sale, the chief operating officer now owns 435,334 shares of the company's stock, valued at approximately $9,037,533.84. This represents a 2.68 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 15.30% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Arcturus Therapeutics
Several institutional investors and hedge funds have recently made changes to their positions in ARCT. nVerses Capital LLC acquired a new position in Arcturus Therapeutics in the third quarter valued at approximately $42,000. Quest Partners LLC lifted its position in shares of Arcturus Therapeutics by 3,283.5% during the 2nd quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company's stock valued at $90,000 after acquiring an additional 3,579 shares during the period. China Universal Asset Management Co. Ltd. boosted its stake in Arcturus Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company's stock worth $121,000 after acquiring an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Arcturus Therapeutics in the second quarter valued at $142,000. Finally, Point72 DIFC Ltd acquired a new position in shares of Arcturus Therapeutics during the second quarter valued at about $188,000. Institutional investors own 94.54% of the company's stock.
About Arcturus Therapeutics
(
Get Free Report)
Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.
Read More
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
